Treatment of anaplastic lymphoma kinase-positive non-small cell lung cancer update and perspectivesRyser, Christoph Olivera; Diebold, Joachimb; Gautschi, OliveraCurrent Opinion in Oncology: January 2019 - Volume 31 - Issue 1 - p 8–12 doi: 10.1097/CCO.0000000000000494 LUNG AND MEDIASTINUM: Edited by Robert Pirker Abstract Author InformationAuthors Article MetricsMetrics Purpose of review We describe recent developments in the rapidly evolving field of anaplastic lymphoma kinase-targeting agents. Recent findings Five targeted drugs are currently available in the clinic via regular approval or named patient programs, including crizotinib, ceritinib, alectinib, brigatinib and lorlatinib. Further drugs are tested in clinical trials. This review summarizes published data, together with drug-specific information on dosing and toxicity. Moreover, we discuss different clinical scenarios and potential treatment options in patients with tumor progression, based on current literature and our own experience. Summary Patients with metastatic, anaplastic lymphoma kinase-rearranged nonsmall cell lung cancer should be managed by interdisciplinary expert teams. New drugs with enhanced brain activity are available, and some patients may benefit from local therapies. aDepartment of Medical Oncology bDepartment of Pathology, Cantonal Hospital of Lucerne, Lucerne, Switzerland Correspondence to Oliver Gautschi, University of Bern, Bern; Cantonal Hospital of Lucerne, 6000 Lucerne, Switzerland. Tel: +41 41 205 58 60; fax: +41 41 205 58 62; e-mail: email@example.com Copyright © 2019 Wolters Kluwer Health, Inc. All rights reserved.